Orionis Biosciences, a Waltham, MA- and Gent, Belgium-based life sciences company, raised $55M in funding.
The round was led by Cormorant Asset Management, and Novartis. Robert Petit joined as Head of Early Clinical Development; Bihua Chen was appointed to the Board of Directors.
The company intends to use the funds for R&D expansion, pipeline growth and advancement of its lead cancer immunotherapy programs into clinical trials.
Led by CEO Nikolai Kley, Orionis Biosciences is advancing a deep pipeline of biologics for the treatment of cancer based on its A-Kine™ platform, which engineers target-selective, conditionally active cytokines designed to trigger anti-tumor immune responses even in “cold” tumors that lack prevalent immune involvement and are refractory to checkpoint inhibitor therapies. A-Kines aim to avoid the systemic toxicities observed with traditional cytokine therapies. In addition, Orionis is developing a diverse spectrum of small molecule molecular glues using its Allo-Glue™ platform, harnessing a first-in-class, genome-scale approach to discovery and rational design of molecular glues in order to reach previously intractable targets.
FinSMEs
19/10/2022